FLGT Fulgent Genetics, Inc.
Healthcare$17.67+3.27%ClosedMarket Cap: $501.8M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.50
P/S
1.52
EV/EBITDA
-8.08
DCF Value
$3.67
FCF Yield
-23.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
38.7%
Operating Margin
-33.1%
Net Margin
-23.0%
ROE
-6.7%
ROA
-6.4%
ROIC
-9.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $71.1M | 30.2% | $-34.6M | $-24.8M | $— | — |
| Q4 null | $83.3M | 39.1% | $-36.2M | $-23.4M | $— | — |
| FY null | $322.7M | 40.6% | $-91.1M | $-60.5M | $— | — |
| Q3 null | $84.1M | 42.2% | $-15.3M | $-6.6M | $— | — |
| Q2 null | $81.8M | 42.1% | $-19.7M | $-19.0M | $— | — |
| Q1 null | $73.5M | 38.6% | $-19.8M | $-11.5M | $— | — |
| Q4 null | $76.2M | 41.8% | $-16.1M | $-5.9M | $— | — |
| FY null | $283.5M | 37.8% | $-73.9M | $-42.7M | $— | — |
| Q3 null | $71.7M | 37.3% | $-17.1M | $-14.6M | $— | — |
| Q2 null | $71.0M | 37.3% | $-18.9M | $-8.7M | $— | — |
| Q1 null | $64.5M | 34.3% | $-21.8M | $-13.5M | $— | — |
| Q4 2023 | $70.5M | 35.8% | $-151.1M | $-128.1M | $-4.30 | — |